CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ('Plus” or the 'Company”), announced today that it has signed a national agreement with UnitedHealthcare ...
C2N Diagnostics, LLC ("C2N"), a specialty diagnostics company with a vision to bring Clarity Through Innovation®, is ...
Alzheimer’s is usually tied to older age, but a new case spotlights a 19-year-old young man with a pattern that resembles the ...
The 2024 McDonald criteria, published just before the 2025 ECTRIMS Congress, substantially expand criteria for a probable diagnosis of multiple sclerosis, experts report.
A new clinical trial published in the New England Journal of Medicine found that among patients with idiopathic ...
Pivotal study met primary endpoint; high-dose AMT-130 demonstrated statistically significant 75% disease slowing at 36 months as measured by ...
The gene therapy company uniQure has announced top-level data from its trial of AMT-130, a new gene therapy designed to treat ...
Glioblastoma is an aggressive and difficult-to-treat cancer, with median survival of just 15 months and fewer than 7% of patients surviving beyond five years. Clinical trials in GBM have a failure ...
Biogen expands its drug delivery solutions by acquiring Alcyone Therapeutics, enhancing patient-centered therapies with the ...
Advertisment हमारे Whatsapp Channel को Join करें In response to this urgent challenge, Dr. Dangs Lab has unveiled Dendrite Dx ...
Bernstein 2nd Annual Global Healthcare Conference September 24, 2025 11:20 AM EDTCompany ParticipantsPriya Singhal - Executive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback